Furthermore, metformin treatment suppressed angiogenesis-related gene expression by downregulating VEGFA, VEGFR2, and NRP1, which highlights its potential to target both apoptotic and angiogenic pathways in breast cancer. The gene discussed is VEGFA; the disease is breast carcinoma.